Although the majority of people with epilepsy have a good prognosis and their seizures can be well controlled with pharmacotherapy, up to one-third of patients can develop drug-resistant epilepsy, especially those patients with partial seizures. This unmet need has driven considerable efforts over the last few decades aimed at developing and testing newer antiepileptic agents to improve seizure control. One of the most promising antiepileptic drugs of the new generation is zonisamide, a benzisoxazole derivative chemically unrelated to other anticonvulsant agents. In this article, the authors present the results of a systematic literature review summarizing the current evidence on the efficacy and tolerability of zonisamide for the treatment of partial seizures. Of particular interest within this updated review are the recent data on the use of zonisamide as monotherapy, as they might open new therapeutic avenues.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-014-0104-1DOI Listing

Publication Analysis

Top Keywords

zonisamide treatment
8
treatment partial
8
partial seizures
8
zonisamide
4
partial epileptic
4
seizures
4
epileptic seizures
4
seizures systematic
4
systematic review
4
review majority
4

Similar Publications

Objective: Numerous studies have been conducted investigating the effects of antiseizure medications (ASMs) on cognitive functions, and the cognitive side effects of some ASMs have been demonstrated. However, data on whether tolerance to these side effects develops over time is insufficient. The aim of this study is to evaluate the reversibility of cognitive impairments caused by ASMs in patients, utilizing event-related potentials (ERPs) and the Montreal Cognitive Assessment (MoCA) test.

View Article and Find Full Text PDF

Introduction: Zonisamide is a medication developed in Japan that is effective for motor symptoms and wearing off in Parkinson's disease (PD). Zonisamide has properties that may improve sleep disorders. The aim of this study is to verify the safety and efficacy of zonisamide for sleep disorders and rapid eye movement (REM) sleep behavioral disorders (RBD) using a mobile two-channel electroencephalography /electrooculography recording system in patients with PD.

View Article and Find Full Text PDF
Article Synopsis
  • * Various smoking cessation methods exist, including nicotine replacement therapies and medications like varenicline and bupropion, with new options like cytisine and faster-acting NRTs being developed, enhancing choices for those trying to quit.
  • * Personalizing cessation strategies by assessing individual responses and preferences can lead to more effective treatment outcomes, including the potential use of combination therapies for those who need additional support.
View Article and Find Full Text PDF

This study explores the therapeutic potential of three proaporphine alkaloids-cissamaline, cissamanine, and cissamdine, which were recently isolated from Cissampelos capensis L.f., against Parkinson's disease (PD).

View Article and Find Full Text PDF

Exploration of the potential association between newer antiseizure medications and arrhythmias: Integrating pharmacovigilance and bioinformatics evidence.

Seizure

December 2024

Department of Pharmacy, Fujian Medical University Union Hospital, 29 Xinquan Rd. Gulou District, Fuzhou, Fujian 350001, China; School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China. Electronic address:

Introduction: Arrhythmias resulting from newer antiseizure medications (ASMs) may significantly impact the safety and quality of life of patients with epilepsy. This study investigated the potential association between new first-line or second-line ASMs and arrhythmias.

Methods: Pharmacovigilance analysis was conducted using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) from 2004 to 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!